Trial Profile
A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate (ALG-1001) as Compared to Avastin® in the Treatment of Diabetic Macular Edema (DME)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Risuteganib (Primary) ; Bevacizumab
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms DEL MAR
- Sponsors Allegro Ophthalmics
- 05 Dec 2018 Status changed from active, no longer recruiting to completed.
- 09 Aug 2017 Primary endpoint (Non-inferiority to bevacizumab in mean change in best-corrected visual acuity-STAGE 2) has been met, according to an Allegro Ophthalmics media release.
- 09 Aug 2017 Results (N=80) from STAGE 2 part pf this trial published in an Allegro Ophthalmics Media Release.